Beam Therapeutics Reports Positive Phase 1/2 Data for BEAM-301 Gene Editing Therapy

Key Facts

1Initial Phase 1/2 data for BEAM-301 demonstrated proof of concept for genetic correction in patients with Glycogen Storage Disease Type Ia.

2Two patients in the 40 mg cohort achieved 15 hours of controlled fasting and no longer required starch supplementation post-treatment.

3Beam Therapeutics plans to engage with the FDA on a potential path to approval for the therapy.

Beam Therapeutics reported positive initial Phase 1/2 clinical data for BEAM-301, demonstrating proof of concept for genetic correction in patients with Glycogen Storage Disease Type Ia. According to a company statement on GlobeNewswire, two patients in the 40 mg cohort achieved 15 hours of controlled fasting and no longer required starch supplementation following the treatment. The company now plans to engage with the FDA to discuss a potential regulatory path to approval for the therapy.

BEAM closed at $23.79 on October 26, 2026, having traded between a day high of $24.11 and a day low of $23.65 during that session. The data, presented at the ESGCT 33rd Annual Congress, provides clinical validation for the company's base editing technology in treating rare metabolic diseases by restoring endogenous glucose production.

Open on chart